Our Funds

Established a portfolio of early stage medical device companies that looked to solve real problems.

Created investment opportunities that allowed direct engagement into company operations.

Continued investing in technologies that improve outcomes & reduce healthcare system costs.

The Opportunity Fund leverages the foundation that the cultivate(MD) Seed and Accelerator Funds have built since 2017. Currently open for investment.
Our Funds

Established a portfolio of early stage medical device companies that looked to solve real problems.

Created investment opportunities that allowed direct engagement into company operations.

Continued investing in technologies that improve outcomes & reduce healthcare system costs.

The Opportunity Fund leverages the foundation that the cultivate(MD) Seed and Accelerator Funds have built since 2017.
Representative Investments

Embody, Inc., is a regenerative medicine company focused on the development and commercialization of implantable medical devices to address the unmet demands in soft tissue restoration and regeneration.

Shoulder Innovations’ InSet™ Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant. IPO on July 31, 2025. Now trading on NYSE under ‘SI’.

SPDx’s solution expands the revenue capacity of any surgical facility. SPDx provides sterile processing and logistic support that unlocks the potential to perform multiple total joints in an ASC.
News and Updates

Shoulder Innovations Announces Full Commercial Launch of the InSet™ 70 Humeral Stem
Expansion of the I-Series Humeral Stem Product Line Further Strengthens Robust Shoulder Arthroplasty Portfolio Grand

Shoulder Innovations Reports Second Quarter 2025 Financial Results
GRAND RAPIDS, Mich., Sept. 9, 2025 /PRNewswire/ — Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI),

Shoulder Innovations Stock Debuts on NYSE Under Ticker “SI”
We’re proud to share that Shoulder Innovations, Inc., a cultivate(MD) portfolio company and leader in

Nanochon Announces Health Canada Approval for First in Human Investigation
Nanochon, a Washington, DC and Baltimore, MD-based orthopedic device biotech company developing an implant for